LPAR6 has a pro-tumorigenic role in HCC [159] by controlling the trans-differentiation of peritumoral tissue fibroblasts (PTFs) into carcinoma-associated fibroblasts (CAFs) [160] and its overexpression leads to a worse clinical outcome in HCC patients [159]. This evidence concerns the gene LPAR6 and hepatocellular carcinoma.